SEC EDGARJUL 22 min read$QURE

Kaye Jack sold $983K of QURE

Kaye Jack sold 21,167 shares of uniQure N.V. (QURE) at an average of $46.44 ($46.43–$46.49, $0.98M total) across 2 trades on 2026-06-30 under a Rule 10b5-1 trading plan.

Original reporting

SEC EDGAR · Kaye Jack

Published Jul 2, 2026, 8:54 PM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Jul 2, 2026, 9:03 PM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

AlphAI market briefInsider activity

Primary signal

$QURE

Neutral

medium confidence

Mentioned

$QURE

Relevance

4/10

AlphAI data visualization · based on SEC EDGAR

Decision brief

The 30-second read

$QURENeutralLow

Why it matters

The newest concrete fact is the disclosed open-market sale size (~21,167 shares; ~$983K) by director Kaye Jack on 2026-06-30 under a 10b5-1 plan.

Market read

Insider-sale disclosures can influence short-term sentiment, but 10b5-1 plans usually reduce interpretive value versus discretionary selling.

What to watch

Traders may over-weight insider sales; without accompanying changes in guidance, trial results, or financing terms, the signal is typically weak.

Relevance 4/10Novelty 6/10Timing: filed after-hours on 2026-07-02; reflects trades dated 2026-06-30

Background

The article is a primary-source SEC Form 4 insider transaction for uniQure N.V. (QURE).

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$QURENeutralMedium confidence

Context

uniQure director Kaye Jack filed a Form 4 selling 21,167 shares in open-market trades on 2026-06-30 for ~$983K under a 10b5-1 plan.

Expected impact

Likely limited near-term impact; any effect should be small and fade unless accompanied by other company-specific news.

Evidence & confidence

The filing is a routine 10b5-1 open-market sale by a director, with no indication of new operational/regulatory/financial developments in the text.

Market effects

Sector

No sector read-through; this is company-specific insider transaction reporting.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Because the sale is explicitly under a pre-arranged 10b5-1 plan, it may be mechanically scheduled and not a bearish signal.

Key entities

issuer
uniQure N.V.
Company whose director insider sale is disclosed via SEC Form 4.
insider
Kaye Jack
Director who sold 21,167 shares in two trades on 2026-06-30.

Read at source ← All news

OCT 8

$QUREHighAI 9/10

Is uniQure (QURE) Undervalued On New Huntingtons Data And FDA Filing Clarity?

uniQure (QURE) shares have fallen 48% in 30 days and 61.41% in 1 year, despite a 3x increase over 3 years. New Phase I/II data showed slowed Huntington's disease progression. Analysts debate if the stock is undervalued at $23.14, with fair value estimates ranging from $62.42 to $353.71, depending on future earnings and FDA approval.

simplywall.st2 min

OCT 7

$QUREHighAI 9/10

Gene Therapy Data Could Be A Big Moment For uniQure Stock (QURE)

uniQure (QURE) reported Phase I/II data for its Huntington’s disease gene therapy, showing slowed disease progression and a manageable safety profile. The FDA previously indicated that 36-month data could support an accelerated approval BLA. Analysts project significant revenue growth, with consensus estimates at $445.8M and earnings of $20.0M by 2029, though the company remains loss-making. The regulatory decision on the BLA is a key near-term focus for investors.

simplywall.st3 min

OCT 5

Med

UniQure Shares Fall After Barclays Downgrade

UniQure's shares declined after Barclays downgraded the company from Overweight to Equal Weight. The stock is currently trading at $22.81, down 2.77% on the day and 41.83% year-to-date. The downgrade is based on a weighted average of ratings including valuation, EPS revisions, and visibility.

marketscreener.com1 min

OCT 5

$QUREMed

QURE Downgraded by Barclays -- Price Target Lowered to $28.00

Barclays downgraded uniQure (QURE) from Overweight to Equal-Weight, lowering its price target from $60.00 to $28.00. The company's GF Value™ is $7.94, suggesting it's 195.5% overvalued. uniQure has a GF Score™ of 49/100, indicating mixed financial performance. Analysts cite concerns over financial health and market conditions.

gurufocus.com2 min

OCT 2

$QUREMedAI 8/10

RBC Capital cuts uniQure stock price target on trial data

RBC Capital reduced its price target for uniQure (QURE) to $48 from $65, citing trial data that missed statistical significance. The stock has fallen 39% in a week. Other analysts maintain bullish outlooks with higher targets. uniQure reported a wider-than-expected Q2 loss but revenue beat estimates. The company has FDA agreements for its Huntington’s disease gene therapy, AMT-130.

investing.com2 min

OCT 1

$QUREHighAI 8/10

uniQure (QURE) Reports New AMT 130 Data As FDA Opens Accelerated Review Path

uniQure (QURE) shared updated Phase I/II data for AMT-130, showing slowed Huntington’s disease progression. The FDA indicated 36-month high-dose data could support accelerated approval. The company focuses on gene therapies for rare conditions, with AMT-130 as a key catalyst.